Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. more
Time Frame | OCUL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.73% | -2.12% | 0.77% |
1-Month Return | -12.07% | -2.54% | 2.65% |
3-Month Return | 14.66% | -6.28% | 12.3% |
6-Month Return | 85% | -1.36% | 13.48% |
1-Year Return | 165.01% | 9.29% | 33.47% |
3-Year Return | 55.66% | 10.05% | 32.22% |
5-Year Return | 120.14% | 43.69% | 92.85% |
10-Year Return | -49.18% | 103.1% | 194.31% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.23M | 17.40M | 43.52M | 51.49M | 58.44M | [{"date":"2019-12-31","value":7.23,"profit":true},{"date":"2020-12-31","value":29.78,"profit":true},{"date":"2021-12-31","value":74.47,"profit":true},{"date":"2022-12-31","value":88.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 2.33M | 2.08M | 4.41M | 4.54M | 5.28M | [{"date":"2019-12-31","value":44.03,"profit":true},{"date":"2020-12-31","value":39.44,"profit":true},{"date":"2021-12-31","value":83.43,"profit":true},{"date":"2022-12-31","value":85.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 1.90M | 15.32M | 39.12M | 46.95M | 53.16M | [{"date":"2019-12-31","value":3.58,"profit":true},{"date":"2020-12-31","value":28.82,"profit":true},{"date":"2021-12-31","value":73.58,"profit":true},{"date":"2022-12-31","value":88.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 45.00% | 88.03% | 89.88% | 91.18% | 90.96% | [{"date":"2019-12-31","value":49.35,"profit":true},{"date":"2020-12-31","value":96.54,"profit":true},{"date":"2021-12-31","value":98.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.76,"profit":true}] |
Operating Expenses | 87.70M | 78.17M | 117.15M | 125.61M | 135.54M | [{"date":"2019-12-31","value":64.71,"profit":true},{"date":"2020-12-31","value":57.67,"profit":true},{"date":"2021-12-31","value":86.43,"profit":true},{"date":"2022-12-31","value":92.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (85.80M) | (62.85M) | (78.04M) | (78.65M) | (82.38M) | [{"date":"2019-12-31","value":-8580200000,"profit":false},{"date":"2020-12-31","value":-6284700000,"profit":false},{"date":"2021-12-31","value":-7803700000,"profit":false},{"date":"2022-12-31","value":-7865400000,"profit":false},{"date":"2023-12-31","value":-8238200000,"profit":false}] |
Total Non-Operating Income/Expense | (5.44M) | (99.39M) | 64.85M | 1.39M | (4.44M) | [{"date":"2019-12-31","value":-8.39,"profit":false},{"date":"2020-12-31","value":-153.27,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":2.15,"profit":true},{"date":"2023-12-31","value":-6.85,"profit":false}] |
Pre-Tax Income | (86.37M) | (155.64M) | (6.55M) | (71.04M) | (80.74M) | [{"date":"2019-12-31","value":-8637200000,"profit":false},{"date":"2020-12-31","value":-15563600000,"profit":false},{"date":"2021-12-31","value":-655300000,"profit":false},{"date":"2022-12-31","value":-7103800000,"profit":false},{"date":"2023-12-31","value":-8073600000,"profit":false}] |
Income Taxes | 3.56M | 4.00M | 4.25M | (7.62M) | 2.82M | [{"date":"2019-12-31","value":83.82,"profit":true},{"date":"2020-12-31","value":93.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-179.16,"profit":false},{"date":"2023-12-31","value":66.22,"profit":true}] |
Income After Taxes | (89.94M) | (159.63M) | (10.80M) | (63.42M) | (83.55M) | [{"date":"2019-12-31","value":-8993500000,"profit":false},{"date":"2020-12-31","value":-15963100000,"profit":false},{"date":"2021-12-31","value":-1080400000,"profit":false},{"date":"2022-12-31","value":-6342200000,"profit":false},{"date":"2023-12-31","value":-8355110500,"profit":false}] |
Income From Continuous Operations | (86.37M) | (155.64M) | (6.55M) | (71.04M) | (67.06M) | [{"date":"2019-12-31","value":-8637200000,"profit":false},{"date":"2020-12-31","value":-15563600000,"profit":false},{"date":"2021-12-31","value":-655300000,"profit":false},{"date":"2022-12-31","value":-7103800000,"profit":false},{"date":"2023-12-31","value":-6705800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (89.94M) | (159.63M) | (10.80M) | (63.42M) | (80.74M) | [{"date":"2019-12-31","value":-8993500000,"profit":false},{"date":"2020-12-31","value":-15963100000,"profit":false},{"date":"2021-12-31","value":-1080400000,"profit":false},{"date":"2022-12-31","value":-6342200000,"profit":false},{"date":"2023-12-31","value":-8073600000,"profit":false}] |
EPS (Diluted) | (1.98) | (2.47) | (0.09) | (0.96) | (1.17) | [{"date":"2019-12-31","value":-198,"profit":false},{"date":"2020-12-31","value":-247,"profit":false},{"date":"2021-12-31","value":-9,"profit":false},{"date":"2022-12-31","value":-96,"profit":false},{"date":"2023-12-31","value":-117,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
OCUL | |
---|---|
Cash Ratio | 11.75 |
Current Ratio | 13.01 |
Quick Ratio | 12.94 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OCUL | |
---|---|
ROA (LTM) | -22.37% |
ROE (LTM) | -72.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OCUL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OCUL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 24.39 |
P/B | 4.24 |
Price/FCF | NM |
EV/R | 18.55 |
EV/Ebitda | NM |
PEG | NM |
Ocular Therapeutix Inc (OCUL) share price today is $9.62
Yes, Indians can buy shares of Ocular Therapeutix Inc (OCUL) on Vested. To buy Ocular Therapeutix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCUL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ocular Therapeutix Inc (OCUL) via the Vested app. You can start investing in Ocular Therapeutix Inc (OCUL) with a minimum investment of $1.
You can invest in shares of Ocular Therapeutix Inc (OCUL) via Vested in three simple steps:
The 52-week high price of Ocular Therapeutix Inc (OCUL) is $11.78. The 52-week low price of Ocular Therapeutix Inc (OCUL) is $3.25.
The price-to-earnings (P/E) ratio of Ocular Therapeutix Inc (OCUL) is
The price-to-book (P/B) ratio of Ocular Therapeutix Inc (OCUL) is 4.24
The dividend yield of Ocular Therapeutix Inc (OCUL) is 0.00%
The market capitalization of Ocular Therapeutix Inc (OCUL) is $1.49B
The stock symbol (or ticker) of Ocular Therapeutix Inc is OCUL